FibroBiologics (FBLG) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FBLG FibroBiologics

Watchlist

2.310
+0.210+10.00%

Close Dec 24 13:00 ET

2.310
0.0000.00%

Post 17:01 ET

80.06MMarket Cap-4.41P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

FibroBiologics Has Entered Into A Standby Equity Purchase Agreement With YA II PN LTD. To Sell Up To $25M In The Aggregate Of Its Common Stock To Yorkville Over The Course Of 2-Years
BenzingaDec 23 08:02 ET
Press Release: FibroBiologics Announces $25 Million Financing
Dow JonesDec 23 07:55 ET
Express News | Fibrobiologics Announces $25 Million Financing
ReutersDec 23 07:55 ET
FibroBiologics Resolves Commitments Through Share Issuance Agreement
TipRanksDec 20 17:47 ET
Rodman & Renshaw Initiates Coverage On FibroBiologics With Buy Rating, Announces Price Target of $12
BenzingaDec 12 05:03 ET · Ratings
FibroBiologics Files Patent Application For Cell-Based Therapeutic For Treatment Of Splenomegaly
BenzingaNov 19 09:16 ET

Comments

Jaguar8

Dec 23 06:55

NEWS

$FibroBiologics (FBLG.US)$
FibroBiologics Announces $25 Million Financing
Monday, 23rd December at 7:55 am
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (th...

Jaguar8

Nov 14 08:16

NEWS

$FibroBiologics (FBLG.US)$
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative...

Jaguar8

Oct 29 08:16

NEWS

$FibroBiologics (FBLG.US)$
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various diff...